Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Omnicell, Inc. $125 Million SEC-Registered At-The-Market Offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Omnicell, Inc. of…
Ablynx NV $230 Million U.S. Initial Public Offering of ADSs and Listing on the NASDAQ
Davis Polk advised the representatives of the several underwriters in connection with Ablynx NV’s offering of $230…
Advanced Accelerator Applications $3.9 billion acquisition by Novartis
Davis Polk is advising Advanced Accelerator Applications S.A. on its $3.9 billion acquisition by Novartis. Entry into…
Davis Polk Advises ViewRay, Inc. on a $50 Million Direct Registered Equity Offering
Davis Polk advised ViewRay, Inc. in a direct registered offering of 8,382,643 shares of ViewRay’s common stock for proceeds…
Davis Polk Advises Auris Medical Holding AG on Its Registered Offering of Common Shares and Equity Line of Financing
Davis Polk advised Auris Medical Holding AG in connection with the SEC-registered offering of $1.5 million of its common…
Flexion Therapeutics, Inc. $122.4 Million Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $122.4 million public offering of 4…
Hologic, Inc. $350 Million Senior Notes Offering
Davis Polk advised the representative of the initial purchasers on a Rule 144A/Regulation S offering by Hologic, Inc…
Deciphera Pharmaceuticals Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,500,000 shares of common stock of…
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offerings of Common Stock and Warrants to Purchase Common Stock
Davis Polk advised Kadmon Holdings, Inc. in connection with an $80.4 million offering of 22,275,000 shares of common stock…
Juno Therapeutics, Inc. $288 Million Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a…